Clinical trials: Hormone Therapy
Hyperparathyroidism
The Effects of Alendronate After Cure of Primary Hyperparathyroidism
We are investigating whether, after surgical cure of primary hyperparathyroidism, alendronate provides even greater beneficial skeletal effects than parathyroidectomy alone.
- Trial name
- AlenPostPara (NCT00359385)
- Testing
- Alendronate 70mg weekly
- Where
- United States
- Sponsor
- Columbia University
Endometriosis, Pelvic Pain
Endometriosis : Traditional Medicine vs Hormone Therapy
This 36-week study will determine whether traditional Chinese medicine (acupuncture and Chinese herbs) is as effective as hormone therapy for alleviating endometriosis-related pelvic pain.
- Trial name
- NCT00034047
- Testing
- Acupuncture, Chinese Products, Nafarelin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Breast Cancer
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
This study is exploring the safety/tolerabtility and preliminary efficacy of the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant for patients with metastatic HR+ breast cancer.
- Trial name
- NCT03959891
- Testing
- Ipatasertib, Fulvestrant, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Massachusetts General Hospital
Growth Hormone Deficiency, Idiopathic Short Stature
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.
- Conditions
- Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small for Gestational Age
- Trial name
- NCT04798690
- Where
- South Korea
- Volunteers
- 5,000 people
- Sponsor
- Dong-A ST Co., Ltd.
Growth Hormone Deficiency, Idiopathic Short Stature
Skeletal Muscle Effects of GH in Boys
The purpose of the study is to measure the functional effects of recombinant GH in skeletal muscle, in addition to growth promotion, in short prepubertal boys with either growth hormone deficiency or idiopathic short stature.
- Trial name
- NCT04020913
- Testing
- Somatropin injection
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Nemours Children's Clinic
Growth Disorders, Growth Failure
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
A prospective, randomized, open-label single-blinded study of 50 subjects with growth hormone deficiency, ages 5 to 15 years in which 25 subjects will initiate rhGH therapy at 0.3mg/kg/week and the remaining 25 subjects will…
- Conditions
- Growth Disorders, Growth Failure, Growth Hormone Treatment, Growth
- Trial name
- NCT06103513
- Testing
- Somatropin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Breast Cancer, Endometrial Cancer
Endometrial Changes in Breast Cancer Women With or Without Hormonal Therapies
A history of breast cancer is a risk factor for the development of endometrial pathologies, such as typical and atypical glandular hyperplasia, endometrial polyps, uterine fibroids, endometrial adenocarcinoma and uterine sarcoma…
- Trial name
- BETA-1 (NCT03898947)
- Testing
- Diagnostic hysteroscopy and targeted endometrial biopsy
- Volunteers
- 1,329 people
- Sponsor
- Università degli Studi dell'Insubria
Acne Vulgaris
The Impact of Baseline Hormonal Profiles (DHEAS, FSH, LH) on Treatment Response to Systemic Isotretinoin in Adult Female Patients With Acne Vulgaris
Acne vulgaris is a common dermatological condition in adult women, often influenced by hormonal factors. Androgens such as dehydroepiandrosterone sulfate (DHEAS) can stimulate sebaceous gland activity, while gonadotropins (FSH…
- Trial name
- NCT07818525
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Biruni University
Major Depressive Disorder, Depression
Effect of the Menstrual Cycle on the Symptoms of Depression and Treatment Response
Objectives: This prospective investigation will compare premenopausal, perimenopausal and postmenopausal women's response to antidepressant medication.
- Trial name
- NCT00188396
- Testing
- Citalopram
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- University Health Network, Toronto
Adult Growth Hormone Deficiency
Versartis International Trial in Adults With Long-Acting Growth Hormone
A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for five months in adults with GHD.
- Trial name
- VITAL (NCT02526420)
- Testing
- somavaratan
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 36 people
- Sponsor
- Versartis Inc.
Menopause, Aging
Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women
Older women have an exaggerated increase in blood pressure during exercise. However, the reasons for this are unclear. It is important to investigate this phenomenon because a greater blood pressure response to exercise has been…
- Conditions
- Menopause, Aging, Blood Pressure
- Trial name
- NCT01633814
- Testing
- Transdermal estradiol
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Diabetic Macular Edema
Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema
The drug being tested in this study is low doses of Optina (formerly known as Danazol) (DMI-5207) that may be an effective treatment for diabetic retinopathy and diabetic macular edema (DME).
- Trial name
- NCT02002403
- Testing
- Danazol
- Volunteers
- 34 people
- Sponsor
- Unity Health Toronto
Breast Cancer
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
Phase II trial to explore the efficacy of vorinostat and tamoxifen combined.
- Trial name
- NCT00365599
- Testing
- suberoylanilide hydroxamic acid (SAHA, Vorinostat), tamoxifen citrate (Tamoxifen)
- Where
- 8 sites in United States
- Volunteers
- 43 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Growth Disorder, Growth Hormone Deficiency in Children
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
This study is conducted in Europe and the United States of America (USA). The aim of the study is to validate two measures for growth hormone deficiency in children, the Treatment Related Impact Measure of Childhood Growth…
- Trial name
- NCT02580032
- Testing
- No treatment given
- Where
- 28 sites in United States, United Kingdom
- Volunteers
- 252 people
- Sponsor
- Novo Nordisk A/S
Metastatic Castration-resistant Prostate Cancer
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)
This is a single-arm, open, single-center clinical study to evaluate the efficacy and safety of RC48-ADC in patients with mCRPC who have progressed after NHT.
- Trial name
- NCT05955209
- Testing
- Disitamab Vedotin（RC48-ADC）
- Volunteers
- 40 people
- Sponsor
- Peking University Cancer Hospital & Institute
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Breast Cancer
ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.
A single centre, single arm phase II study of alternating eribulin and hormonal therapy in 12 patients with locally advanced or metastatic breast cancer who have received at least one hormonal therapy and at least one…
- Trial name
- ALERT (NCT02681523)
- Testing
- Eribulin
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Breast Cancer, Premenopausal Breast Cancer
Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer
Although combination endocrine therapy has been associated with significant reduction in risk of recurrence in younger women with hormone receptor positive breast cancer, it has been associated with more adverse effects and…
- Conditions
- Breast Cancer, Premenopausal Breast Cancer, Hormone Receptor Positive Tumor
- Trial name
- MyCHOICE (NCT03407768)
- Testing
- Individualized interventions
- Where
- 2 sites in Canada
- Volunteers
- 41 people
- Sponsor
- University of Saskatchewan
Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
This phase II trial studies the effect of onapristone and anastrozole in treating patients with hormone receptor positive endometrial cancer that has not responded to previous treatment (refractory).
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT04719273
- Testing
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Thomas Jefferson University